207_Combined course Presentations

PCV x 4 + RT vs RT alone: RTOG 9402



289 AA or AOA patients  Randomization to receive either 4 PCV (procarbazine, lomustine, vincristine) followed by RT 59.4 Gy/33 fr or RT alone  No differences in term of median OS between the 2 arms (4.9 vs 4.7 years)  PFS benefit for patients receiving PCV + RT (2.6 vs 1.7 years)

 Higher rates of G3-G4 toxicity in patients receiving PCV+RT (65%), with at least 1 fatal event.  1p/19q codeletion is a favorable prognostic factor (median OS >7 vs 2.8 years)

Cairncross G. et al. JCO 2006;24